SUPPLY OF SIROLIMUS-ELUTING STENT FOR HDFRZ

This tender is for the supply of a sirolimus-eluting stent (SES) intended for use at HDFRZ. A sirolimus-eluting stent is a type of coronary stent coated with sirolimus, an antiproliferative drug. This drug is released slowly over time to prevent restenosis, the re-narrowing of a blood vessel after angioplasty or stenting. The abbreviation 'HDFRZ' likely refers to a specific healthcare facility or a regional health department, indicating the intended end-user or location for the stent deployment. The procurement will specify the required stent dimensions (length, diameter), elution profile of the sirolimus, and any specific technical features such as deliverability or radiopacity. Quality certifications, such as CE marking or FDA approval, will likely be mandatory. The tender documents will detail the quantity of stents required, packaging specifications, sterilization methods, and delivery schedules. The goal is to ensure a consistent supply of high-quality SES to support cardiac interventions at the designated facility, improving patient outcomes by reducing the risk of recurrent blockages. Bidders must prove their ability to meet stringent medical device standards and regulatory requirements.

This is a services contract in the health and medical services and general supplies sectors. Located in Chile, Latin America, this opportunity is open to firms and consortiums.

Published through Chile Mercado Publico, a national government procurement portal. Public procurement tenders follow the country's national bidding regulations and may have specific eligibility and documentation requirements for services in the health and medical services sector. Service contracts are typically evaluated on both technical quality and price, and may require bidders to demonstrate relevant experience and qualified personnel. This contract has already been awarded. The information is published for transparency and market intelligence purposes.